The latest price target for Xenon Pharmaceuticals (NASDAQ:XENE) was reported by RBC Capital on June 18, 2024. The analyst firm set a price target for $55.00 expecting XENE to rise to within 12 months (a possible 52.27% upside). 21 analyst firms have reported ratings in the last year.

The latest analyst rating for Xenon Pharmaceuticals (NASDAQ:XENE) was provided by RBC Capital, and Xenon Pharmaceuticals reiterated their outperform rating.

There is no last upgrade for Xenon Pharmaceuticals

There is no last downgrade for Xenon Pharmaceuticals.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Xenon Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Xenon Pharmaceuticals was filed on June 18, 2024 so you should expect the next rating to be made available sometime around June 18, 2025.

While ratings are subjective and will change, the latest Xenon Pharmaceuticals (XENE) rating was a reiterated with a price target of $55.00 to $55.00. The current price Xenon Pharmaceuticals (XENE) is trading at is $36.12, which is out of the analyst’s predicted range.